Literature DB >> 12854169

Expression of local renin and angiotensinogen mRNA in cirrhotic portal hypertensive patient.

Li Zhang1, Zhen Yang, Bao-Min Shi, Da-Peng Li, Chong-Yun Fang, Fa-Zu Qiu.   

Abstract

AIM: To investigate the expression of local renin and angiotensinogen mRNA in cirrhotic portal hypertensive patients.
METHODS: The expression of local renin and angiotensinogen mRNA in the liver, splenic artery and vein of PH patients was detected by RT-PCR analysis.
RESULTS: Expression of local renin mRNA in the liver of control group was (0.19+/-0.11), significantly lower than that in splenic artery (0.45+/-0.17) or splenic vein(0.39+/-0.12) respectively, (P<0.05). Expression of local angiotensinogen mRNA in the liver was (0.64+/-0.21), significantly higher than that in splenic artery(0.41+/-0.15) or in splenic vein (0.35+/-0.18) respectively, (P<0.05). Expression of local renin mRNA in the liver, splenic artery and vein of PH group was (0.78+/-0.28), (0.86+/-0.35) and (0.81+/-0.22) respectively, significantly higher than that in the control group, (P<0.05). Expression of local angiotensinogen mRNA in the liver, splenic artery and vein of PH group was (0.96+/-0.25), (0.83+/-0.18) and (0.79+/-0.23) respectively, significantly higher than that in the control group, (P<0.05). There was no significant difference between the liver, splenic artery and vein in the expression of local renin or local angiotensinogen mRNA in PH group, (P<0.05).
CONCLUSION: In normal subjects the expression of local renin and angiotensinogen mRNA was organ specific, but with increase of the expression of LRAS, the organ-specificity became lost in cirrhotic patients. LRAS may contribute to increased resistance of portal vein with liver and formation of splanchnic vasculopathy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12854169      PMCID: PMC4615510          DOI: 10.3748/wjg.v9.i7.1584

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  39 in total

1.  Endothelin activates the vascular renin-angiotensin system in rat mesenteric arteries.

Authors:  H Rakugi; Y Tabuchi; M Nakamaru; M Nagano; K Higashimori; H Mikami; T Ogihara
Journal:  Biochem Int       Date:  1990-08

2.  Fat-storing cells as liver-specific pericytes. Spatial dynamics of agonist-stimulated intracellular calcium transients.

Authors:  M Pinzani; P Failli; C Ruocco; A Casini; S Milani; E Baldi; A Giotti; P Gentilini
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

3.  Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis.

Authors:  J R Jonsson; A D Clouston; Y Ando; L I Kelemen; M J Horn; M D Adamson; D M Purdie; E E Powell
Journal:  Gastroenterology       Date:  2001-07       Impact factor: 22.682

4.  Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF.

Authors:  G A Ferns; E W Raines; K H Sprugel; A S Motani; M A Reidy; R Ross
Journal:  Science       Date:  1991-09-06       Impact factor: 47.728

5.  Effects of AT1 receptor antagonist, losartan, on rat hepatic fibrosis induced by CCl(4).

Authors:  Hong-Shan Wei; Ding-Guo Li; Han-Ming Lu; Yu-Tao Zhan; Zhi-Rong Wang; Xin Huang; Jing Zhang; Ji-Lin Cheng; Qin-Fang Xu
Journal:  World J Gastroenterol       Date:  2000-08       Impact factor: 5.742

6.  Host genetic factors influence disease progression in chronic hepatitis C.

Authors:  E E Powell; C J Edwards-Smith; J L Hay; A D Clouston; D H Crawford; C Shorthouse; D M Purdie; J R Jonsson
Journal:  Hepatology       Date:  2000-04       Impact factor: 17.425

7.  Pathological morphology alteration of the splanchnic vascular wall in portal hypertensive patients.

Authors:  Zhen Yang; Li Zhang; Dapeng Li; Fazu Qiu
Journal:  Chin Med J (Engl)       Date:  2002-04       Impact factor: 2.628

8.  Role of prostacyclin in the splanchnic hyperemia contributing to portal hypertension.

Authors:  J V Sitzmann; G B Bulkley; M C Mitchell; K Campbell
Journal:  Ann Surg       Date:  1989-03       Impact factor: 12.969

9.  Loss of angiotensin-II receptors in portal hypertensive rabbits.

Authors:  J V Sitzmann; Y Wu; G Aguilera; P A Cahill; R C Burns
Journal:  Hepatology       Date:  1995-08       Impact factor: 17.425

10.  Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis.

Authors:  A W Schneider; J F Kalk; C P Klein
Journal:  Hepatology       Date:  1999-02       Impact factor: 17.425

View more
  1 in total

1.  TMEM16A regulates portal vein smooth muscle cell proliferation in portal hypertension.

Authors:  Xi Zeng; Ping Huang; Mingkai Chen; Shiqian Liu; Nannan Wu; Fang Wang; Jing Zhang
Journal:  Exp Ther Med       Date:  2017-11-08       Impact factor: 2.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.